antiviral news

Press Releases in the global landscape
Jun 11, 2024

Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect

NanoViricides, Inc. reports that its clinical stage lead nanoviricide broad-spectrum antiviral drug candidate, NV-387, results in an ideal flat blood concentration profile for an extended time period upon oral administration in two different animal models.
Read More »
Jun 10, 2024

Pfizer’s Paxlovid Ineffective Against Long COVID Using 15-Day Regimen: Study

While a prolonged, 15-day regimen of Paxlovid is safe, it appears to be ineffective at lowering the symptoms of long COVID, according to results of a Phase II trial funded by Pfizer and conducted by Stanford Medicine.
Read More »
Jun 10, 2024

Paxlovid tied to 34% lower risk of hospitalization in adolescent COVID patients

No safety concerns were reported after Paxlovid use.
Read More »
Jun 8, 2024

Paxlovid does not quell long Covid symptoms: Stanford study

The study was funded by Pfizer, which also collaborated on the design and execution of the trial.
Read More »
Jun 7, 2024

Clinical trial shows 15-day Paxlovid regimen safe but adds no clear benefit for long COVID

In a clinical trial conducted by Stanford Medicine investigators and their colleagues, a 15-day course of Paxlovid—an antiviral drug combination targeting SARS-CoV-2, the virus that causes COVID-19—proved safe as an extended-duration treatment but didn't lessen select symptoms of the syndrome known as long COVID: the persistence, or reappearance, of COVID-related symptoms three months or more after an initial COVID-19 infection.
Read More »
Jun 7, 2024

Pfizer's Paxlovid ineffective in treating long COVID symptoms: study

Pfizer's Paxlovid ineffective in treating long COVID symptoms: study.
Read More »